189 related articles for article (PubMed ID: 22323448)
1. Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma.
Nishikawa H; Maeda Y; Ishida T; Gnjatic S; Sato E; Mori F; Sugiyama D; Ito A; Fukumori Y; Utsunomiya A; Inagaki H; Old LJ; Ueda R; Sakaguchi S
Blood; 2012 Mar; 119(13):3097-104. PubMed ID: 22323448
[TBL] [Abstract][Full Text] [Related]
2. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance.
Yoshida N; Abe H; Ohkuri T; Wakita D; Sato M; Noguchi D; Miyamoto M; Morikawa T; Kondo S; Ikeda H; Nishimura T
Int J Oncol; 2006 May; 28(5):1089-98. PubMed ID: 16596224
[TBL] [Abstract][Full Text] [Related]
3. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.
Errington JA; Conway RM; Walsh-Conway N; Browning J; Freyer C; Cebon J; Madigan MC
Br J Ophthalmol; 2012 Mar; 96(3):451-8. PubMed ID: 22190731
[TBL] [Abstract][Full Text] [Related]
5. Cancer/testis (CT) antigens: potential targets for immunotherapy.
Caballero OL; Chen YT
Cancer Sci; 2009 Nov; 100(11):2014-21. PubMed ID: 19719775
[TBL] [Abstract][Full Text] [Related]
6. Expression of cancer-testis antigens in esophageal cancer and their progress in immunotherapy.
Zhang Y; Zhang Y; Zhang L
J Cancer Res Clin Oncol; 2019 Feb; 145(2):281-291. PubMed ID: 30656409
[TBL] [Abstract][Full Text] [Related]
7. Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma.
Gjerstorff MF; Pøhl M; Olsen KE; Ditzel HJ
BMC Cancer; 2013 Oct; 13():466. PubMed ID: 24103781
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.
Ishihara M; Kageyama S; Miyahara Y; Ishikawa T; Ueda S; Soga N; Naota H; Mukai K; Harada N; Ikeda H; Shiku H
BMC Cancer; 2020 Jun; 20(1):606. PubMed ID: 32600281
[TBL] [Abstract][Full Text] [Related]
9. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer.
Groeper C; Gambazzi F; Zajac P; Bubendorf L; Adamina M; Rosenthal R; Zerkowski HR; Heberer M; Spagnoli GC
Int J Cancer; 2007 Jan; 120(2):337-43. PubMed ID: 17066423
[TBL] [Abstract][Full Text] [Related]
10. Centrosomal localisation of the cancer/testis (CT) antigens NY-ESO-1 and MAGE-C1 is regulated by proteasome activity in tumour cells.
Pagotto A; Caballero OL; Volkmar N; Devalle S; Simpson AJ; Lu X; Christianson JC
PLoS One; 2013; 8(12):e83212. PubMed ID: 24340093
[TBL] [Abstract][Full Text] [Related]
11. [Targeting cancer antigen (MAGE-A4, NY-ESO -1) for immunotherapy].
Imai N; Ikeda H; Shiku H
Nihon Rinsho; 2012 Dec; 70(12):2125-9. PubMed ID: 23259384
[TBL] [Abstract][Full Text] [Related]
12. NY-ESO-1/LAGE-1 coexpression with MAGE-A cancer/testis antigens: a tissue microarray study.
Bolli M; Schultz-Thater E; Zajac P; Guller U; Feder C; Sanguedolce F; Carafa V; Terracciano L; Hudolin T; Spagnoli GC; Tornillo L
Int J Cancer; 2005 Jul; 115(6):960-6. PubMed ID: 15751033
[TBL] [Abstract][Full Text] [Related]
13. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
14. Cancer/testis antigen expression and autologous humoral immunity to NY-ESO-1 in gastric cancer.
Wang Y; Wu XJ; Zhao AL; Yuan YH; Chen YT; Jungbluth AA; Gnjatic S; Santiago D; Ritter G; Chen WF; Old LJ; Ji JF
Cancer Immun; 2004 Nov; 4():11. PubMed ID: 15516106
[TBL] [Abstract][Full Text] [Related]
15. Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1.
Maio M; Coral S; Sigalotti L; Elisei R; Romei C; Rossi G; Cortini E; Colizzi F; Fenzi G; Altomonte M; Pinchera A; Vitale M
J Clin Endocrinol Metab; 2003 Feb; 88(2):748-54. PubMed ID: 12574209
[TBL] [Abstract][Full Text] [Related]
16. Expression of cancer/testis (CT) antigens in lung cancer.
Tajima K; Obata Y; Tamaki H; Yoshida M; Chen YT; Scanlan MJ; Old LJ; Kuwano H; Takahashi T; Takahashi T; Mitsudomi T
Lung Cancer; 2003 Oct; 42(1):23-33. PubMed ID: 14512184
[TBL] [Abstract][Full Text] [Related]
17. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma.
Wölfl M; Jungbluth AA; Garrido F; Cabrera T; Meyen-Southard S; Spitz R; Ernestus K; Berthold F
Cancer Immunol Immunother; 2005 Apr; 54(4):400-6. PubMed ID: 15449039
[TBL] [Abstract][Full Text] [Related]
18. Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?
Tessari A; Pilla L; Silvia D; Duca M; Paolini B; Carcangiu ML; Mariani L; de Braud FG; Cresta S
Breast; 2018 Dec; 42():68-73. PubMed ID: 30189381
[TBL] [Abstract][Full Text] [Related]
19. Expression and significance of cancer testis antigens in primary mucosal melanoma of the head and neck.
Prasad ML; Jungbluth AA; Patel SG; Iversen K; Hoshaw-Woodard S; Busam KJ
Head Neck; 2004 Dec; 26(12):1053-7. PubMed ID: 15515159
[TBL] [Abstract][Full Text] [Related]
20. Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma.
Dyrskjøt L; Zieger K; Kissow Lildal T; Reinert T; Gruselle O; Coche T; Borre M; Ørntoft TF
Br J Cancer; 2012 Jun; 107(1):116-22. PubMed ID: 22596240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
